Segulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies

Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies  oversubscribed and upsized $245 million Series D equity financing round. This financing is the largest ever private funding round for a dialysis device company.

“We are excited to help contribute to and support Quanta’s commitment to modernise and overhaul the outdated treatment paradigm in hemodialysis treatment, which has not seen substantial innovation for several decades” said Roger Gunnarsson, SMA’s Managing Partner.

 “The SC+ system is an innovative cartridge-based invention that is compact, simple, and powerful. It is set to fundamentally change the way that dialysis care is provided, in every setting from specialized dialysis centres to acute care hospitals, and increasingly moving into the home.  With this growth capital, Quanta has the resources to drive improved patient outcomes and convenience while accelerating market penetration and scale.”

The funding will allow the UK-company Quanta to scale up global operations with a focus on the United States, where SC+ received 510(k) clearance from the FDA in December for use in acute and chronic care facilities. The company is investing in significant infrastructure to scale up manufacturing, sales and customer service functions to support use in currently approved care settings within the United States, while also preparing to launch a study to support its future FDA clearance for in-home use within the United States.   

“We are delighted to attract such a strong syndicate of investors, which represents a clear vote of confidence in our innovative approach to dialysis treatment,” said John E. Milad, CEO of Quanta.

“Everybody knows that dialysis care must improve. For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient, while simplifying complexity and reducing the overall cost of care. Our small, simple-to-use, and powerful dialysis system SC+ is positioned to help transform kidney care. The funding we are announcing today will allow us to accelerate our emergence as a significant force in this market.”

The financing round was led by Glenview Capital and co-led by Novo Holdings, with support from a broad group of other top-tier investors, including BlackRock, Eldridge, Sands Capital, Millennium, Monashee Investment Management LLC., Puhua Capital, Segulah Medical Acceleration and Ancora, alongside Orlando Health, an integrated delivery network. Existing shareholders also participated in the round, including Wellington Partners, btov, Seroba Life Sciences and The Grands. 

“Innovation in kidney dialysis has been stagnant for too long – but the demand from patients, doctors, health care providers and payors for new, better and more flexible solutions is impossible to ignore,” said Johan de Ruiter, Chairman of Quanta.

“We are excited to scale up our operations, enabling us to provide access to this critical new technology that will save lives, improve patients’ quality of life and lower healthcare costs.”

For more information about Segulah Medical Acceleration, please contact:

SMA
Roger Gunnarsson (gunnarsson@segulahmedical.com)
+46 73 850 67 32

About Hemodialysis

Hemodialysis is a life sustaining treatment for patients with kidney failure to help normalize blood chemistry and remove waste products and excess fluids.

About Quanta and SC+

Quanta is enabling the future of kidney care, with a mission to bring to market solutions that improve the delivery of dialysis and help people live more freely. Headquartered in the UK and with operations in the US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator. Quanta’s lead product, SC+, is a small and simple, powerful hemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments. In the US, SC+ is FDA cleared for use in acute and chronic care facilities, and in the UK, it is CE marked, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home.  The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis. Meanwhile, as a compact, portable and versatile device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.

Learn more at Quantadt.com.

About Segulah Medical Acceleration

Segulah Medical Acceleration (SMA) is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe. SMA’s objective is to help its partner companies accelerate growth and reach commercial proof of concept. SMA’s geographic remit is Scandinavia and other Western European countries. The areas within Medtech that SMA prioritizes include medical devices and consumables, diagnostics, life science tools, and digital technologies (AI). SMA has more than SEK 1.25 billion (€ 125m equivalent) in investable funds. segulahmedical.com